Emerging evidence supports a key role for the gut microbiota in metabolic diseases, including type 2 diabetes (T2D) and obesity. The dipeptidyl peptidase-4 inhibitor vildagliptin is highly efficacious
With the increasing prevalence of diabetes, the incidence rate of diabetic kidney disease (DKD) has risen yearly in China. While traditional therapies like renin-angiotensin system blockers remain fou
Unpublished and published liraglutide studies in humans - Completed before Jan 2011 Unpublished (n=37): 68.5% Published (n=17): 31.5% ----> 3.1 papers per registry _____________
